Understanding how some bacteria resist treatment with cefiderocol
Official title: Mechanisms of cefiderocol nonsusceptibility and resistance evolution in carbapenem-resistant pathogens
Funded at Univ of Arkansas for Med Scis · NIH-10803156 · Data updated 2026-11-12
This study is looking into why some tough bacteria, like Acinetobacter and Enterobacterales, don't respond to a new antibiotic called cefiderocol, so we can find better ways to treat infections caused by these germs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $728,695 |
| NIH project number | 1R01AI175440-01A1 |
| Project ID | NIH-10803156 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with infections caused by carbapenem-resistant Acinetobacter or Enterobacterales.
✕Less likely to help
Patients with infections caused by bacteria that are not carbapenem-resistant may not benefit from this research.
What this research studies
This research investigates the mechanisms behind antibiotic resistance in certain bacteria, specifically focusing on carbapenem-resistant Acinetobacter and Enterobacterales. It aims to understand why some strains of these bacteria are not susceptible to cefiderocol, a newer antibiotic approved for treating such infections. By examining genetic factors and the phenomenon of heteroresistance, the study seeks to uncover why some bacteria can survive treatment, which could lead to improved strategies for managing these difficult infections.
Why it matters
Potential benefit: If successful, this research could lead to better treatment options for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Previous research has shown success in understanding antibiotic resistance mechanisms in other bacterial species, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Univ of Arkansas for Med Scis
Little Rock, United States Active
Researchers
- Principal investigator: Huang, En — Univ of Arkansas for Med Scis
- Study coordinator: Huang, En
Related research
Other NIH-funded projects on the same topics.
-
Postpartum depression screening at well-child visits in Arkansas
A study examines whether adding depression screening at baby visits in Arkansas improves detection and care for new mothers.
-
How the RORα protein affects breast cancer growth and inflammation
Researchers are looking at whether boosting the RORα protein in breast cells can lower harmful oxidative stress and immune inflammation that help breast cancer grow.
-
PLOD2 and succinate: a metabolic switch that fuels breast cancer spread
A cancer research project is exploring how a metabolic change involving succinate and a key enzyme (PLOD2) may drive breast cancer cells to become more invasive and able to spread.
-
Stopping steroid-related muscle and bone wasting in Duchenne muscular dystrophy
Researchers are testing ways to protect muscles and bones in people with Duchenne muscular dystrophy who take long-term steroid medicines.
-
STAR+ Model for Hearing Diagnostics and Treatment in Rural Appalachian Children
A program that uses telehealth to connect rural school children with hearing specialists so they can get timely testing and treatment for hearing loss.
-
Organoid model to study how malaria and EBV drive Burkitt lymphoma in children
A study uses human tonsillar organoids to understand how malaria parasite infection and EBV together may cause a type of lymphoma in children from sub-Saharan Africa.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.